Xu Ting, Yang Xiao-Qun, Jiang Kai-Ling, Wang Hui, Ma Peng-Peng, Zhong Liang, Liu Bei-Zhong
Central Laboratory of Yong-Chuan Hospital, Chongqing Medical University, Chongqing 400016, P.R. China.
Key Laboratory of Laboratory Medical Diagnostics, Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, P.R. China.
Oncol Rep. 2017 Feb;37(2):986-994. doi: 10.3892/or.2017.5357. Epub 2017 Jan 9.
Promyelocytic leukemia-retinoic acid receptor α (PML-RARα) is a fusion protein generated by the t(15;17)(q22;q12) translocation associated with acute promyelocytic leukemia (APL). PML-RARα is cleaved by neutrophil elastase, an early myeloid-specific serine protease, leading to translocation of the nuclear localization signal (NLS) of the PML protein to the N-terminal of RARα, and the mutational product PML(NLS-). The present study was designed to analyze the role of the NLS in mediating PML transport into the nucleus and to evaluate the value of measuring NLS translocation in the early diagnosis of APL. PML and PML(NLS-) localization was examined by immunofluorescence (IF). The interaction between PML/PML(NLS-) and importin α was detected by an in vivo binding assay using co-immunoprecipitation and double IF labeling. Twenty-seven untreated APL patients with PML-RARα and 22 non-APL controls were evaluated. PML(NLS-) was detected in primary APL, but not non-APL cells. IF showed that PML was localized to the nucleus, interacted with importin α in vivo, and co-localized in the PML nuclear bodies. PML(NLS-) was primarily localized in the cytoplasm and the interaction with importin α was lost. IF had a sensitivity and specificity of 92.6 and 77.3%, respectively, for diagnosing APL. These data suggest that PML(NLS-) may be a novel diagnostic biomarker for APL.
早幼粒细胞白血病-维甲酸受体α(PML-RARα)是一种由与急性早幼粒细胞白血病(APL)相关的t(15;17)(q22;q12)易位产生的融合蛋白。PML-RARα被中性粒细胞弹性蛋白酶切割,中性粒细胞弹性蛋白酶是一种早期髓系特异性丝氨酸蛋白酶,导致PML蛋白的核定位信号(NLS)易位至RARα的N端,产生突变产物PML(NLS-)。本研究旨在分析NLS在介导PML转运至细胞核中的作用,并评估检测NLS易位在APL早期诊断中的价值。通过免疫荧光(IF)检测PML和PML(NLS-)的定位。使用免疫共沉淀和双重IF标记的体内结合试验检测PML/PML(NLS-)与输入蛋白α之间的相互作用。对27例未经治疗的伴有PML-RARα的APL患者和22例非APL对照进行评估。在原发性APL细胞中检测到PML(NLS-),但在非APL细胞中未检测到。IF显示PML定位于细胞核,在体内与输入蛋白α相互作用,并在PML核体中共定位。PML(NLS-)主要定位于细胞质,与输入蛋白α的相互作用丧失。IF诊断APL的敏感性和特异性分别为92.6%和77.3%。这些数据表明PML(NLS-)可能是APL的一种新型诊断生物标志物。